Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
OBJECTIVE
To test the hypothesis that decrease in DNA methylation will increase the expression of cancer-testis antigens (CTA) and class I major histocompatibility complex (MHC)-encoded molecules by ovarian cancer cells, and thus increase the ability of these cells to be recognized by antigen-reactive CD8(+) T cells.


METHODS
Human ovarian cancer cell lines were cultured in the presence or absence of varying concentrations of the DNA demethylating agent 5-aza-2'-deoxycytidine (DAC) for 3-7 days. The expression levels of 12 CTA genes were measured using the polymerase chain reaction. The protein expression levels of class I MHC molecules and MAGE-A1 were measured by flow cytometry. T cell reactivity was determined using interferon-gamma ELISpot analysis.


RESULTS
DAC treatment of ovarian cancer cell lines increased the expression of 11 of 12 CTA genes tested including MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, NY-ESO-1, TAG-1, TAG-2a, TAG-2b, and TAG-2c. In contrast, DAC treatment decreased the already low expression of the MAGE-A2 gene by ovarian cancer cells, a finding not previously observed in cancers of any histological type. DAC treatment increases the expression of class I MHC molecules by the cells. These effects were time-dependent over a 7-day interval, and were dose-dependent up to 1-3 microM for CTA and up to 10 microM for class I MHC molecules. Each cell line tested had a unique pattern of gene upregulation after exposure to DAC. The enhanced expression levels increased the recognition of 2 of 3 antigens recognized by antigen-reactive CD8(+) T cells.


CONCLUSIONS
These results demonstrate the potential utility of combining DAC therapy with vaccine therapy in an attempt to induce the expression of antigens targeted by the vaccine, but they also demonstrate that care must be taken to target inducible antigens.
Adair
Sara J
SJ
Department of Surgery, Human Immune Therapy Center, University of Virginia, Box 801359, Charlottesville, VA 22908, USA.
Hogan
Kevin T
KT
D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000187:drug effects / Q000276:immunology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects* / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis* / Q000187:drug effects / Q000276:immunology; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000276:immunology; D016133:Polymerase Chain Reaction; D015854:Up-Regulation
D000951:Antigens, Neoplasm; D000964:Antimetabolites, Antineoplastic; D015395:Histocompatibility Antigens Class I; D000077209:Decitabine; D001374:Azacitidine
J Cell Physiol. 2003 Mar;194(3):272-88
12548548
Blood. 2003 Jun 1;101(11):4644-6; discussion 4645-6
12756166
J Immunother. 2001 Mar-Apr;24(2):151-61
11265773
Int J Cancer. 2001 Jun 1;92(5):703-11
11340576
Cancer Res. 1983 Nov;43(11):5379-89
6604576
J Clin Pathol. 2001 Sep;54(9):669-74
11533070
Leuk Res. 2002 Dec;26(12):1113-8
12443884
Mol Pharmacol. 2004 Jan;65(1):18-27
14722233
Cancer Res. 1985 Aug;45(8):3668-76
4016745
J Natl Cancer Inst. 2002 Jun 5;94(11):805-18
12048268
Semin Cancer Biol. 2002 Feb;12(1):3-13
11926409
Cancer Res. 1988 Jun 15;48(12):3355-9
2897238
J Cell Physiol. 2006 Apr;207(1):58-66
16252259
Cancer Invest. 2002;20(2):222-36
11901543
Hum Immunol. 1982 Aug;5(1):49-59
6981636
Int J Cancer. 2003 Jun 20;105(3):430-1; author reply 432-3
12704681
Gynecol Oncol. 1988 Sep;31(1):103-12
3410341
J Immunol. 2005 Mar 1;174(5):3080-6
15728523
J Immunother. 1999 Jan;22(1):16-24
9924695
Ann Thorac Surg. 2001 Jan;71(1):295-301; discussion 301-2
11216765
Cancer J Sci Am. 1999 Jan-Feb;5(1):16-7
10188055
Lancet Oncol. 2003 Feb;4(2):104-9
12573352
Immunogenetics. 1994;40(5):360-9
7927540
Mol Cancer Res. 2006 May;4(5):339-49
16687489
Clin Cancer Res. 2007 Nov 1;13(21):6386-95
17975151
Clin Cancer Res. 1996 Sep;2(9):1619-25
9816341
Ann Oncol. 1997 Apr;8(4):369-72
9209667
J Immunol. 1998 Oct 1;161(7):3598-606
9759882
J Immunol. 1979 Jul;123(1):342-9
87477
Carcinogenesis. 2001 Oct;22(10):1615-23
11577000
Genomics. 1997 Dec 15;46(3):397-408
9441743
Int J Cancer. 1992 Nov 11;52(5):839-41
1428237
Cancer Res. 2004 Feb 1;64(3):1157-63
14871852
Mol Cancer. 2007 Jan 25;6:10
17254359
Br J Cancer. 2000 Aug;83(4):493-7
10945497
Immunogenetics. 1994;39(2):121-9
8276455
Int J Cancer. 2001 Jun 15;92(6):856-60
11351307
In Vitro Cell Dev Biol Anim. 2000 Jun;36(6):357-61
10949993
Science. 1990 Sep 28;249(4976):1570-4
2218499
Clin Cancer Res. 2007 Jun 1;13(11):3333-8
17545540
Cancer Res. 2006 Jan 15;66(2):1105-13
16424047
Biochem Biophys Res Commun. 2003 Jul 18;307(1):52-63
12849980
Br J Cancer. 2002 Mar 18;86(6):979-82
11953832
Clin Cancer Res. 2006 Oct 1;12(19):5777-85
17020984
Mol Cancer. 2008 May 22;7:43
18498645
Cancer Res. 1994 Apr 1;54(7):1766-71
7511051
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7149-53
8692960
Immunogenetics. 1983;18(1):23-35
6190744
Cancer Res. 2000 Mar 15;60(6):1654-62
10749136
Cancer Immunol Immunother. 2008 Jan;57(1):31-42
17579858
Cancer Immun. 2004 Jan 23;4:1
14738373
Int J Cancer. 2001 Oct 15;94(2):243-51
11668505
Clin Cancer Res. 2002 Aug;8(8):2690-5
12171902
J Natl Cancer Inst. 1977 Feb;58(2):209-14
833871
Mol Cell Biol. 1999 Nov;19(11):7327-35
10523621
Hybridoma. 1982;1(2):87-90
6208124
Anticancer Res. 2003 May-Jun;23(3A):1969-96
12894571
Cancer Res. 1991 Oct 1;51(19):5181-7
1717140
Cancer Res. 2004 Dec 15;64(24):9167-71
15604288